BRC News

A UK biotech company based on UCL research has raised $33 million from investors to begin early-phase trials of a potential new treatment for people with severe epilepsy.

A new spinout company will advance digital transformation at NHS organisations and international healthcare providers to improve patient care, patient safety and population health and research.

The NIHR has committed £16 million to the trial.

The research from a BRC supported team is published in the New England Journal of Medicine.

The BRC-supported research team will run a clinical trial of LungVax over the next four years.

The development of the breakthrough immunotherapy has had long-standing support from the BRC at UCLH.

In the current financial year, UCLH has recruited the first participant in the world to three clinical trials.

BRC-supported researchers are among many UCL academics named in the internationally recognised Clarivate listings.

A new daily pill has shown continuous, round-the-clock control of high blood pressure in people whose condition is difficult to manage.

Major UCL-led study finds that sertraline, one of the most commonly prescribed antidepressants, improves core symptoms of depression such as low mood and suicidal thoughts within two weeks.

The global study is taking place in 18 countries.

A patient with motor neurone disease was able to control a computer just by using his thoughts following the surgery at UCLH.

With CAR T cell therapy proven to be effective in blood cancer patients, researchers are turning to testing the treatment in autoimmune conditions such as lupus and now MS.

The £26 million project is accelerating the search for effective treatments.

A study shows it is possible to cut the time for diagnostic MRI scans for dementia to one third of their standard length.